[Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Bio-Rad insider transaction summary: EVP and President, LSG Barry James reported transactions on 09/01/2025 involving Bio-Rad Laboratories Class A common stock (BIO). The filing shows 602 shares were acquired and added to his direct holdings following the vesting of restricted stock units, increasing his direct beneficial ownership to 748.555 shares. The filing also reports a disposition of 217 shares sold at $297.88 per share, leaving 531.555 shares after that sale. Separately, the report lists restricted stock unit activity: 178 units vested (converted to 0 shares remaining), 174 units vested and remain as 174 shares, and 250 units vested increasing total RSU-derived shares to 502. The transactions are documented on a Form 4 signed 09/02/2025.

Positive

• Acquisition of 602 shares through RSU vesting increased direct beneficial ownership to 748.555 shares
• Detailed RSU grant history provided showing grant years (2021, 2022, 2023) and vesting schedules, supporting transparency

Negative

• Disposition of 217 shares at $297.88 per share reduced direct holdings to 531.555 shares

Insights

Securities Analyst

TL;DR: Insider realized partial proceeds while receiving vested equity, leaving net direct holdings modestly adjusted.

The Form 4 shows both acquisitions from RSU vesting and a contemporaneous sale. 602 shares were recorded as acquired through vesting and 217 shares were sold at $297.88 per share. The net effect is an increase in total reported direct beneficial ownership from these awards but a partial monetization via sale. For investors, these are routine executive compensation events rather than extraordinary corporate actions; they reflect scheduled vesting and an executed disposition documented under Section 16 reporting rules.

Corporate Governance Expert

TL;DR: Transactions reflect standard equity compensation vesting and a reported sale, consistent with customary insider reporting.

Barry James is identified as an officer (EVP, President, LSG) and filed as a single reporting person. The explanations specify the vested RSUs originate from grants on 09/01/2021, 09/01/2022, and 09/01/2023 with four-year vesting schedules. The Form 4 includes clear accounting of shares acquired on vesting and shares sold. From a governance perspective, the disclosure appears complete and timely based on the filing content provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BARRY JAMES

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, President, LSG

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/01/2025		M		602(1)	A	$0	748.555	D
Bio-Rad A Common Stock	09/01/2025		F		217	D	$297.88	531.555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/01/2025		M			178	(3)	(3)	Bio-Rad A Common Stock	178	$0	0	D
Restricted Stock Units	$0(2)	09/01/2025		M			174	(4)	(4)	Bio-Rad A Common Stock	174	$0	174	D
Restricted Stock Units	$0(2)	09/01/2025		M			250	(5)	(5)	Bio-Rad A Common Stock	250	$0	502	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. On September 1, 2021, the reporting person was granted 709 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

4. On September 1, 2022, the reporting person was granted 694 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

5. On September 1, 2023, the reporting person was granted 1,002 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ James Barry	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did BIO (Bio-Rad Laboratories) report on 09/01/2025?

The filing reports that Barry James acquired 602 shares via RSU vesting and sold 217 shares at $297.88 per share on 09/01/2025.

How many Bio-Rad shares does Barry James beneficially own after these transactions?

The Form 4 shows 531.555 shares beneficially owned following the reported sale and 748.555 shares after the RSU acquisition before the sale is reflected, per the table entries.

What caused the acquisition of shares reported by the insider?

The acquisition resulted from the vesting of restricted stock units (RSUs), with the filing noting RSUs granted in 2021, 2022, and 2023 that vest in four equal annual installments.

What grant years and sizes are disclosed for the RSUs in this filing?

The filing references grants on 09/01/2021 (709 RSUs), 09/01/2022 (694 RSUs), and 09/01/2023 (1,002 RSUs), each vesting in four equal annual installments.

When was the Form 4 signed by the reporting person?

The Form 4 is signed by Barry James on 09/02/2025 as shown in the filing.